Your browser doesn't support javascript.
loading
Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model.
Nobori, Haruaki; Fukao, Keita; Kuroda, Takayuki; Anan, Naomi; Tashima, Ryoichi; Nakashima, Masaaki; Noda, Sayuri; Tajiri, Minako; Torii, Mikinori; Toba, Shinsuke; Uemura, Kentaro; Sanaki, Takao; Shishido, Takao; Tachibana, Yuki; Kato, Teruhisa.
Afiliação
  • Nobori H; Pharmaceutical Research Division, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Fukao K; Pharmaceutical Research Division, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Kuroda T; Pharmaceutical Research Division, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Anan N; Pharmaceutical Research Division, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Tashima R; Pharmaceutical Research Division, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Nakashima M; Pharmaceutical Research Division, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Noda S; Pharmaceutical Research Division, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Tajiri M; Pharmaceutical Research Division, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Torii M; Pharmaceutical Research Division, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Toba S; Pharmaceutical Research Division, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Uemura K; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Kita-20, Nishi-10 Kita-ku, Sapporo, Hokkaido 001-0020, Japan.
  • Sanaki T; Pharmaceutical Research Division, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Shishido T; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Kita-20, Nishi-10 Kita-ku, Sapporo, Hokkaido 001-0020, Japan.
  • Tachibana Y; Laboratory of Biomolecular Science, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6 Kita-ku, Sapporo, Hokkaido 060-0812, Japan.
  • Kato T; Pharmaceutical Research Division, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
J Antimicrob Chemother ; 77(11): 2984-2991, 2022 10 28.
Article em En | MEDLINE | ID: mdl-35914182
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Tratamento Farmacológico da COVID-19 Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Tratamento Farmacológico da COVID-19 Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article